Émilie Degagné, Paul D Donohoue, Suparna Roy, Jessica Scherer, Tristan W Fowler, Ryan T Davis, Gustavo A Reyes, George Kwong, Morena Stanaway, Vanina Larroca Vicena, Devin Mutha, Raymond Guo, Leslie Edwards, Benjamin Schilling, McKay Shaw, Stephen C Smith, Bryan Kohrs, Heinrich J Kufeldt, Glen Churchward, Finey Ruan, David B Nyer, Kyle McSweeney, Matthew J Irby, Christopher K Fuller, Lynda Banh, Mckenzi S Toh, Matthew Thompson, Arthur L G Owen, Zili An, Scott Gradia, Justin Skoble, Mara Bryan, Elizabeth Garner, Steven B Kanner
Allogeneic chimeric antigen receptor (CAR) T-cell therapies hold the potential to overcome many of the challenges associated with patient-derived (autologous) CAR T cells. Key considerations in the development of allogeneic CAR T-cell therapies include prevention of GvHD and suppression of allograft rejection. Here we describe preclinical data supporting the ongoing first-in-human clinical study, the CaMMouflage trial (NCT05722418), evaluating CB-011 in patients with relapsed/refractory multiple myeloma. CB-011 is a hypoimmunogenic, allogeneic anti-B cell maturation antigen (BCMA) CAR T-cell therapy candidate...
February 9, 2024: Cancer Immunology Research